An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS in Patients with Atopic Dermatitis
To evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
28
topical treatment
Taro Pharmaceuticals USA Inc.
Hawthorne, New York, United States
The Number of Patients in the Study With HPA Axis Suppression
Hypothalamic Pituitary Adrenal (HPA) Axis Response to a stimulator
Time frame: 29 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.